Parallax Volatility Advisers
RGNX icon

Parallax Volatility Advisers’s Regenxbio RGNX Stock Holding History

Parallax Volatility Advisers’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,000
Closed -$194K – 2847
2020
Q1 		$194K Buy
+6,000
New +$250K ﹤0.01% 1990

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's RGNX Position: Q2 2020 in Review

Parallax Volatility Advisers sold out of Regenxbio (RGNX) in Q2 2020, closing a stake of 1,742 shares — an estimated $56K sold.

Parallax Volatility Advisers first reported a position in RGNX in Q4 2017 and held it in 2 quarters. The position peaked at $140K in Q4 2017. 179 funds tracked by Wall St. Rank hold RGNX as of Q2 2020.

  • Parallax Volatility Advisers reported no remaining Regenxbio position as of Q2 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,742 Regenxbio shares in Q2 2020, an estimated $56K.
  • Parallax Volatility Advisers first reported a position in Regenxbio in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Regenxbio position peaked at $140K in Q4 2017.
  • 179 funds tracked by Wall St. Rank held Regenxbio as of Q2 2020.

Based on Parallax Volatility Advisers's 13F filing for Q2 2020, filed 14 Aug 2020.